BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33021440)

  • 1. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
    Klotz L; Pavlovich CP; Chin J; Hatiboglu G; Koch M; Penson D; Raman S; Oto A; Fütterer J; Serrallach M; Relle J; Lotan Y; Heidenreich A; Bonekamp D; Haider M; Tirkes T; Arora S; Macura KJ; Costa DN; Persigehl T; Pantuck AJ; Bomers J; Burtnyk M; Staruch R; Eggener S
    J Urol; 2021 Mar; 205(3):769-779. PubMed ID: 33021440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
    Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study.
    Nair SM; Hatiboglu G; Relle J; Hetou K; Hafron J; Harle C; Kassam Z; Staruch R; Burtnyk M; Bonekamp D; Schlemmer HP; Roethke MC; Mueller-Wolf M; Pahernik S; Chin JL
    BJU Int; 2021 May; 127(5):544-552. PubMed ID: 33037765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
    Ghai S; Perlis N; Lindner U; Hlasny E; Haider MA; Finelli A; Zlotta AR; Kulkarni GS; van der Kwast TH; McCluskey SA; Kucharczyk W; Trachtenberg J
    Eur Radiol; 2018 Oct; 28(10):4281-4287. PubMed ID: 29696431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial.
    Ghai S; Finelli A; Corr K; Chan R; Jokhu S; Li X; McCluskey S; Konukhova A; Hlasny E; van der Kwast TH; Incze PF; Zlotta AR; Hamilton RJ; Haider MA; Kucharczyk W; Perlis N
    Radiology; 2021 Mar; 298(3):695-703. PubMed ID: 33529137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate.
    Bonekamp D; Wolf MB; Roethke MC; Pahernik S; Hadaschik BA; Hatiboglu G; Kuru TH; Popeneciu IV; Chin JL; Billia M; Relle J; Hafron J; Nandalur KR; Staruch RM; Burtnyk M; Hohenfellner M; Schlemmer HP
    Eur Radiol; 2019 Jan; 29(1):299-308. PubMed ID: 29943185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
    Eggener SE; Yousuf A; Watson S; Wang S; Oto A
    J Urol; 2016 Dec; 196(6):1670-1675. PubMed ID: 27449263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance.
    Natarajan S; Jones TA; Priester AM; Geoghegan R; Lieu P; Delfin M; Felker E; Margolis DJA; Sisk A; Pantuck A; Grundfest W; Marks LS
    J Urol; 2017 Oct; 198(4):839-847. PubMed ID: 28396184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference Standard.
    Ramsay E; Mougenot C; Staruch R; Boyes A; Kazem M; Bronskill M; Foster H; Sugar L; Haider M; Klotz L; Chopra R
    J Urol; 2017 Jan; 197(1):255-261. PubMed ID: 27545572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial.
    Natarajan S; Raman S; Priester AM; Garritano J; Margolis DJ; Lieu P; Macairan ML; Huang J; Grundfest W; Marks LS
    J Urol; 2016 Jul; 196(1):68-75. PubMed ID: 26748164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial.
    Sundaram KM; Staruch R; Burtnyk M; Lane JS; Penson DF; Arora SS
    J Vasc Interv Radiol; 2020 May; 31(5):740-746.e4. PubMed ID: 32307311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
    Orczyk C; Barratt D; Brew-Graves C; Peng Hu Y; Freeman A; McCartan N; Potyka I; Ramachandran N; Rodell R; Williams NR; Emberton M; Ahmed HU
    J Urol; 2021 Apr; 205(4):1090-1099. PubMed ID: 33315505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review.
    Dora C; Clarke GM; Frey G; Sella D
    J Endourol; 2022 Jun; 36(6):841-854. PubMed ID: 35029127
    [No Abstract]   [Full Text] [Related]  

  • 14. Relief of Lower Urinary Tract Symptoms After MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Subgroup Analyses in Patients with Concurrent Cancer and Benign Prostatic Hyperplasia.
    Elterman D; Li W; Hatiboglu G; Relle J; Zorn KC; Bhojani N; Chin J
    J Endourol; 2021 Apr; 35(4):497-505. PubMed ID: 32935575
    [No Abstract]   [Full Text] [Related]  

  • 15. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters.
    Hatiboglu G; Popeneciu V; Bonekamp D; Burtnyk M; Staruch R; Pahernik S; Tosev G; Radtke JP; Motsch J; Schlemmer HP; Hohenfellner M; Nyarangi-Dix JN
    World J Urol; 2020 Feb; 38(2):343-350. PubMed ID: 31062122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial.
    Jones TA; Chin J; Mcleod D; Barkin J; Pantuck A; Marks LS
    J Urol; 2018 Jan; 199(1):133-139. PubMed ID: 28652121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes.
    Shoji S; Nakano M; Fujikawa H; Endo K; Hashimoto A; Tomonaga T; Terachi T; Uchida T
    Int J Urol; 2015 Nov; 22(11):1043-9. PubMed ID: 26251127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study.
    Ehdaie B; Tempany CM; Holland F; Sjoberg DD; Kibel AS; Trinh QD; Durack JC; Akin O; Vickers AJ; Scardino PT; Sperling D; Wong JYC; Yuh B; Woodrum DA; Mynderse LA; Raman SS; Pantuck AJ; Schiffman MH; McClure TD; Sonn GA; Ghanouni P
    Lancet Oncol; 2022 Jul; 23(7):910-918. PubMed ID: 35714666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological, Oncologic and Functional Outcomes of a Prospective Registry of Salvage High Intensity Focused Ultrasound Ablation for Radiorecurrent Prostate Cancer.
    Siddiqui KM; Billia M; Arifin A; Li F; Violette P; Chin JL
    J Urol; 2017 Jan; 197(1):97-102. PubMed ID: 27422297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.